Fluid compartmental shifts with efficacious pioglitazone therapy in overweight monkeys: implications for peroxisome proliferator-activated receptor-γ agonist use in prediabetes

被引:10
|
作者
Kavanagh, Kylie [1 ]
Brown, Kathleen K. [2 ]
Berquist, Mandy L. [2 ]
Zhang, Li [1 ]
Wagner, Janice D. [1 ]
机构
[1] Wake Forest Univ, Comparat Med Sect, Dept Pathol, Sch Med, Winston Salem, NC 27127 USA
[2] GlaxoSmithKline, Res Triangle Pk, NC USA
来源
METABOLISM-CLINICAL AND EXPERIMENTAL | 2010年 / 59卷 / 06期
基金
美国国家卫生研究院;
关键词
LOWERS BLOOD-PRESSURE; PPAR-GAMMA; INSULIN SENSITIVITY; FAT DISTRIBUTION; BODY-WATER; ROSIGLITAZONE; RETENTION; VOLUME; THIAZOLIDINEDIONES; EXPRESSION;
D O I
10.1016/j.metabol.2010.02.010
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Pioglitazone is prescribed to improve insulin sensitivity in type 2 diabetes mellitus patients and has been discussed as a therapy for metabolic syndrome. Pioglitazone and other thiazolidinediones are associated with fluid retention and edema that may exacerbate existing or developing congestive heart failure, which is often present in these patients. Using a nonhuman primate model, our aims were to evaluate (1) whether fluid shifts were detectable in normoglycemic monkeys, (2) which fluid compartment changed, and (3) whether fluid retention was dose dependent. Seventeen adult male cynomolgus macaques (Macaca fascicularis) were studied in a Latin square design such that all animals received 0, 1, 2, and 5 mg/kg pioglitazone for 6 weeks with 2 weeks of washout between dosing intervals. Doses approximated human exposures achieved with 30, 45, and 60 mg. At the end of each period, animals were weighed and underwent dual-absorption x-ray absorption scanning for body composition measurements. Fluid volumes were quantitated by Evans blue dilution for plasma volume, equilibration of sodium bromide for extracellular water, and deuterated water for total body water. Significant (P < .05) effects were seen with expansion of PV at both the 2- and 5-mg/kg doses, along with reduced plasma sodium at 5 mg/kg; however, surrogate end points used to indicate fluid retention (body weight, hematocrit, total protein, and albumin) did not change significantly. Significant trends toward increases in interstitial fluid and extracellular water with increasing dose were apparent. Pioglitazone effectively improved metabolic status by significantly decreasing fasting glucose and triglycerides and increasing adiponectin. We conclude that thiazolidinedione-related plasma volume expansion occurs in nondiabetic primates and that fluid retention is detectable when compartments are directly measured. (C) 2010 Elsevier Inc. All rights reserved.
引用
收藏
页码:914 / 920
页数:7
相关论文
共 50 条
  • [11] Pioglitazone, a Peroxisome Proliferator-Activated Receptor γ Agonist, Suppresses Rat Prostate Carcinogenesis
    Suzuki, Shugo
    Mori, Yukiko
    Nagano, Aya
    Naiki-Ito, Aya
    Kato, Hiroyuki
    Nagayasu, Yuko
    Kobayashi, Mizuho
    Kuno, Toshiya
    Takahashi, Satoru
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2016, 17 (12):
  • [12] Peroxisome proliferator-activated receptor-γagonist pioglitazone reduces the development of necrotizing enterocolitis in a neonatal preterm rat model
    Corsini, Iuri
    Polvani, Simone
    Tarocchi, Mirko
    Tempesti, Sara
    Marroncini, Giada
    Generoso, Marta
    Bresci, Cecilia
    Gozzini, Elena
    Bianconi, Tommaso
    Galli, Andrea
    Dani, Carlo
    PEDIATRIC RESEARCH, 2017, 81 (02) : 364 - 368
  • [13] Peroxisome Proliferator-activated Receptor-γ Agonist Pioglitazone Ameliorates White Matter Lesion and Cognitive Impairment in Hypertensive Rats
    Lan, Lin-Fang
    Zheng, Lu
    Yang, Xian
    Ji, Xiao-Tan
    Fan, Yu-Hua
    Zeng, Jin-Sheng
    CNS NEUROSCIENCE & THERAPEUTICS, 2015, 21 (05) : 410 - 416
  • [14] The peroxisome proliferator-activated receptor-γ agonist pioglitazone protects against cisplatin-induced renal damage in mice
    Jesse, Cristiano R.
    Bortolatto, Cristiani F.
    Wilhelm, Ethel A.
    Roman, Silvane Souza
    Prigol, Marina
    Nogueira, Cristina W.
    JOURNAL OF APPLIED TOXICOLOGY, 2014, 34 (01) : 25 - 32
  • [15] Transcriptional regulation of nephrin gene by peroxisome proliferator-activated receptor-γ agonist:: Molecular mechanism of the antiproteinuric effect of pioglitazone
    Benigni, Ariela
    Zoja, Carla
    Tomasoni, Susanna
    Campana, Marco
    Corna, Daniela
    Zanchi, Cristina
    Gagliardini, Elena
    Garofano, Elvira
    Rottoli, Daniela
    Ito, Takahito
    Remuzzi, Giuseppe
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2006, 17 (06): : 1624 - 1632
  • [16] Peroxisome proliferator-activated receptor-γ agonist pioglitazone reduces the development of necrotizing enterocolitis in a neonatal preterm rat model
    Iuri Corsini
    Simone Polvani
    Mirko Tarocchi
    Sara Tempesti
    Giada Marroncini
    Marta Generoso
    Cecilia Bresci
    Elena Gozzini
    Tommaso Bianconi
    Andrea Galli
    Carlo Dani
    Pediatric Research, 2017, 81 : 364 - 368
  • [17] Protective effects of a peroxisome proliferator-activated receptor-β/δ agonist in experimental autoimmune encephalomyelitis
    Polak, PE
    Kalinin, S
    Dello Russo, C
    Gavrilyuk, V
    Sharp, A
    Peters, JM
    Richardson, J
    Willson, TM
    Weinberg, G
    Feinstein, DL
    JOURNAL OF NEUROIMMUNOLOGY, 2005, 168 (1-2) : 65 - 75
  • [18] Antitumor action of the peroxisome proliferator-activated receptor-γ agonist rosiglitazone in hepatocellular carcinoma
    Bo, Qi-Fu
    Sun, Xiu-Mei
    Liu, Jin
    Sui, Xiao-Mei
    Li, Gui-Xin
    ONCOLOGY LETTERS, 2015, 10 (04) : 1979 - 1984
  • [19] Antioxidative, antinitrative, and vasculoprotective effects of a peroxisome proliferator-activated receptor-γ agonist in hypercholesterolemia
    Tao, L
    Liu, HR
    Gao, E
    Teng, ZP
    Lopez, BL
    Christopher, TA
    Ma, XL
    Batinic-Haberle, I
    Willette, RN
    Ohlstein, EH
    Yue, TL
    CIRCULATION, 2003, 108 (22) : 2805 - 2811
  • [20] Regulation of adiponectin receptors in hepatocytes by the peroxisome proliferator-activated receptor-γ agonist rosiglitazone
    Sun, X
    Han, R
    Wang, Z
    Chen, Y
    DIABETOLOGIA, 2006, 49 (06) : 1303 - 1310